文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

V-safe:截至2023年6月美国CDC主动安全监测系统报告的新冠疫苗接种后发现总结

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.
PubMed 文献 · Vaccine · 2026-06-30

V-safe是疫情期间建立的主动监测系统,通过短信健康调查收集美国居民接种新冠疫苗后的症状与健康影响。2020年12月14日至2023年6月30日共9,609,282人完成至少一次调查,多为女性、25-64岁、接种mRNA疫苗。健康影响在接种后第一周、第二剂后及mRNA-1273接种者中更常见,成人mRNA疫苗第1-6剂后第一周报告寻求医疗照护的比例为0.8-1.2%。

要点

  • V-safe共纳入9,609,282名完成至少一次调查的参与者,95.0%接种mRNA疫苗。
  • 健康影响在首剂后第一周、第二剂后及mRNA-1273接种者中报告更频繁。
  • 成人mRNA疫苗第1-6剂后第一周报告寻求医疗照护的比例为0.8-1.2%。

核心结论

  • V-safe监测到的健康影响模式与既往V-safe分析和临床试验数据相似。
  • 疫情期间参与度快速下降,提示未来紧急疫苗安全监测可考虑激励措施以提高调查完成率。

研究设计与样本

  • V-safe是美国CDC开发的主动安全监测系统,接种后居民可注册接收短信健康调查。
  • 调查在接种后按日、周、月间隔询问症状及健康影响,包括无法完成日常活动、上班上学或寻求医疗照护。
  • 分析时间段为2020年12月14日至2023年6月30日,共9,609,282人完成至少一次调查。

主要发现

  • 参与者中女性占62.2%,25-64岁占69.2%,接种mRNA疫苗者占95.0%。
  • 与美国接种人群相比,非西班牙裔白人或亚裔及≥75岁人群比例更高。
  • 多数人在其年龄组推荐接种后最初几个月内注册V-safe,并在接种后第一周内完成初始健康调查。
  • 后续剂次参与度下降,尤其是<18岁人群。
  • 健康影响在接种后第一周、第二剂相比第一剂、以及mRNA-1273相比BNT162b2接种者中报告更频繁;<12岁儿童报告健康影响略少于成人。

关键数值与推荐

  • 成人接种mRNA疫苗第1-6剂后第一周报告寻求医疗照护的比例为0.8-1.2%。

临床怎么用

  • V-safe数据可用于补充临床试验和被动监测,了解新冠疫苗接种后自我报告的健康影响模式。
  • 主动监测系统需关注参与度随时间下降的问题,未来可探索激励措施维持调查完成率。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

V-safe is an active surveillance system developed during the pandemic to monitor COVID-19 vaccine safety. After vaccination, US residents could enroll to receive text messages linked to health check-in surveys. Questions about symptoms and health impacts, including inability to complete daily activities, attend work or school, or receipt of medical care were asked at daily, weekly, and monthly intervals after vaccination. We describe demographics of participants compared to the vaccinated population, trends in enrollment, participation over time, and self-reported health impacts in the V-safe population during the COVID-19 pandemic. During December 14, 2020 - June 30, 2023, 9,609,282 persons completed at least one V-safe survey. Most were female (62.2%), aged 25-64 years (69.2%), and received an mRNA vaccine (95.0%). Compared to the US vaccinated population, a higher proportion of participants were non-Hispanic White or Asian and ≥ 75 years. Most registered for V-safe within the first few months after vaccination was recommended for their age group. Most completed an initial health survey within the first week after vaccination. Participation decreased for successive doses, especially among persons aged <18 years. Health impacts were reported more frequently during the first week post-vaccination, after dose 2 compared to dose 1, and among recipients of mRNA-1273 vaccine compared to recipients of BNT162b2 vaccine. Health impacts among children <12 years were reported slightly less frequently compared to adults. Seeking medical care was reported in the first week after vaccination by 0.8-1.2% of adults after doses 1-6 of an mRNA vaccine. Findings were similar to those in previous V-safe analyses and data from clinical trials. Rapidly decreasing participation during the course of the pandemic suggests that incentives encouraging survey completion in V-safe could be useful for improving safety monitoring for future emergency vaccines. V-safe continues to collect data about COVID-19 vaccines, with an emphasis on new products.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Myers TR, Zauche LH, Marquez PL, et al. V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023. Vaccine. 2026. PMID: 42378925. doi:10.1016/j.vaccine.2026.128725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。